The adoption of Wegovy, a {semaglutide-based|GLP-1 receptor therapy, in the UK has prompted thorough evaluation and the creation of specific protocols for its use. Current national stance emphasizes that Wegovy is primarily intended for individuals with a body mass index (BMI) of 30 or greater, or those with associated comorbidities such as diabete